What’s Wrong With BioTech in Japan – Molcure

Japan could be, and perhaps should be, a BioTech startup powerhouse. The size of the market, the aging population and the depth and quality of the fundamental research being done here should make Japan a global player. But something is holding her back. Today we talk to Yutaro Kyono and Yoichiro Hara, two of the co-founders of Molcure about the challenges facing BioTech in Japan and how they have managed to get around them. The Molcure system greatly reduces the time and resources to develop anti-body based drugs by identifying candidate gene sequences and automating the testing of those candidates. But Molcure's vision is bigger than that. They envision a system so automated and complete they refer to it as “Sample in. Cure Out" It’s an amazingly ambitious plan, even in the startup world, and they have some big challenges ahead of them. It’s a great story from an ambitious team, and I think you’ll enjoy the conversation.